Abbott Laboratories [NYSE:ABT] price is worthing noting Friday. The current price is $111.07 with a high of $109.97 and $108.80. Analysts see the the current price target is $116.94.
To ground this price against the rest of the market, over the last two 52 weeks, the company is trading 36.82%, while the S&P 500 is trading 1.11%. Traders should note that the company’s next earning date is 10/21/2020. The company has price per sales of 6.11 and price per cash flow of 89.51.
Wait and see
Holding a Market Cap of $192.17 billion, Abbott Laboratories has seen a trading range over the last year of $61.61-$114.19.
For the last five days, ABT is up from its last closing price. The average shares trading hands each day is 5.30M, with average 10-day volume coming in at 4.1 million.
Using a Force Index Indicator is a good way to look at how strong actual buying and selling pressure is for ABT. When we apply the Elder Force Index to Abbott Laboratories, we are seeing an Elder Force Indicator number of 1327832.06.
The recent performance of the stock is another area that can tell traders how to proceed. ABT is presenting an interesting case. This can be seen in the Forward P/E ratio, which currently stands at 26.29. Moreover, the company’s enterprise value has gone from $176.48B to $154.33B quarter-over-quarter. Obviously, the company is heading in the wrong direction, but there are still opportunities for growth in the sector.
In the last quarter, ABT made a profit of 4.07 billion. Abbott Laboratories also saw quarter revenue growth year over year of 4.34%. In addition, the company has operating cash flow of $6.4 billion.
Looking at popular technical indicators, the company’s 5-day moving average is 108.59 compared to the 50-day moving average of 106.04. So, we are clearly seeing an upward trajectory here.
The Relative Strength Index or RSI is an indicator ranging between 0 and 100 that traders use to determine if a stock is “overbought” or “oversold.” A strong uptrend tending to reach into the “overbought” status is above 70, while a downward trend will stay around the 30 mark. ABT currently holds a 9-day RSI of 65.08%, while 100-day RSI stands at 55.62%.
Another indicator we believe is worth keeping tabs on is the Moving Average Convergence Divergence or MACD. Similar to the concept of the Force Index — on the basis of price momentum — the MACD gives traders a tool to measure the turning point of a stock even during rapid fluctuations in price. Buy and sell signals are determined by a stock’s relation to the zero line, so if a stock is above a zero line for many weeks it might be a “buy.” On the other hand, if a stock is below the zero line consistently, it might be one to stay away from. Also, if the MACD line reaches a peak and dips, its momentum may be waning. ABT’s 9-day MACD is 1.27 and the company’s 100-day MACD stands at 10.71.
Another area that is important to analyze is insider moves and majority shareholders. While this is not always an error-free way to tell what the future holds for a stock, you can maybe gather important information from reading the tea leaves about who is buying and selling.
The major holders for this stock are 0.73% by insiders and 77.18% by institutions. Regarding institutional holdings, Vanguard Group, Inc. (The) owns 19.47%, while the second top holder, Blackrock Inc., currently owns 17.49%.
Over the last six months, insiders have sold 30,000 with the most recent transaction from Wainer Andrea F, Executive Vice President, with a sell at price 107.01 per share.
Overall, the recommended rating for ABT is Strong Buy. Currently, the company has 19 analysts watching the stock, and the average quarterly earnings estimate is 0.9. Quarterly revenue estimates are averaging 8.5B with the high estimate reaching 8.79B and the low at 8.15B.
To review, the current 1-year target estimate is sitting at 115.53, while the current price 111.07. Based on this, we expect the stock to rise considering the aforementioned fundamentals.